Evidence map›Paper›PMID 42846509›Full record

ArticleFrontiers in microbiology2026

A C39-like protein from methanogenic archaea: structural insights and functional divergence in β-galactose analogue degradation.

Leizhou Guo, Liuyan Wang, Liping Bai

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Leizhou GuoKey Laboratory of Southwest China Wildlife Resources Conservation (Ministry of Education), College of Life Science, China West Normal University, Nanchong, Sichuan, China.
Liuyan WangTraditional Chinese Medicine Health Industry Promotion Center in Dongxing District, Neijiang, China.
Liping BaiKey Laboratory of Southwest China Wildlife Resources Conservation (Ministry of Education), College of Life Science, China West Normal University, Nanchong, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methanogenic archaea harbor diverse enzymes that support their survival in extreme environments and play key roles in global carbon cycling. The C39 peptidase family, known for cleaving peptide substrates, now gains functional expansion through A0A126R2S0, a novel enzyme that shares structural homology with C39 peptidases (RMSD: 2.0-2.5 Å) but exhibits glycosidase activity. The enzyme harbors a conserved Q-C-H motif in which the third residue of the canonical catalytic triad is substituted from aspartate to asparagine. Enzymatic assays demonstrate that A0A126R2S0 specifically hydrolyzes β-D-galactose analogs, such as p-nitrophenyl-β-D-galactopyranoside (PNPG, Sub 5), with an activity of 16.15 ± 0.71 μM/h, which is 7.8-fold higher than that toward α-configured analogs. Notably, it shows no detectable activity toward double-glycine peptides or archaeal cell wall polypeptides, distinguishing it from canonical C39 peptidases. Truncation experiments confirm that the C-terminal domain alone is sufficient for this glycosidase activity. Molecular docking and site-directed mutagenesis further implicate Loop 3 (residues D314-D324) as a critical determinant of substrate recognition, with the C316-C322 disulfide bond likely stabilizing its conformation. Collectively, these findings expand the functional repertoire of the C39 peptidase superfamily, suggest an evolutionary connection between peptidases and glycosidases, and establish A0A126R2S0 as a candidate biocatalyst for β-galactoside processing.

Indexed as

C39-like proteinglycosidase activitymethanogenic archaeastructure and functionβ-Galactose analogs

Identifiers

PMID42846509
PMCPMC13642728

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.